| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,055 | -2,667 |
| Depreciation and amortization | 0 | 0 |
| Share-based compensation expense | 318 | 227 |
| Write-off of acquired intangible asset | 0 | - |
| Write-off of goodwill | 0 | - |
| Change in fair value of warrants | -294 | -294 |
| Gain on disposal of property and equipment | 0 | - |
| Deferred tax benefit | 0 | - |
| Prepaid expenses and other current assets | -649 | -360 |
| Other assets | 1 | 1 |
| Accounts payable | -841 | -1,073 |
| Accrued expense | -227 | -246 |
| Other liabilities | 0 | 0 |
| Cash used in operating activities | -4,451 | -3,694 |
| Proceeds from sale of property and equipment | 0 | - |
| Cash provided by investing activities | 0 | - |
| Proceeds from the sale of common stock in private placement | 635 | 635 |
| Cash provided by financing activities | 635 | 635 |
| Net decrease in cash and cash equivalents | -3,816 | -3,059 |
| Cash and cash equivalents at beginning of period | 8,289 | - |
| Cash and cash equivalents at end of period | 4,473 | - |
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. (GRTX)